PPA
VERV

Parametric Portfolio Associates’s Verve Therapeutics VERV Stock Holding History

Parametric Portfolio Associates’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-8,511
Closed -$314K – 3768
2021
Q4 		$314K Buy
+8,511
New +$358K ﹤0.01% 3271

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Parametric Portfolio Associates's VERV Position: Q1 2022 in Review

Parametric Portfolio Associates sold out of Verve Therapeutics (VERV) in Q1 2022, closing a stake of 8,511 shares — an estimated $314K sold.

Parametric Portfolio Associates first reported a position in VERV in Q4 2021 and held it in 1 quarter. The position peaked at $314K in Q4 2021. 92 funds tracked by Wall St. Rank hold VERV as of Q1 2022.

  • Parametric Portfolio Associates reported no remaining Verve Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Parametric Portfolio Associates sold 8,511 Verve Therapeutics shares in Q1 2022, an estimated $314K.
  • Parametric Portfolio Associates first reported a position in Verve Therapeutics in Q4 2021 and held it in 1 quarter.
  • Parametric Portfolio Associates's Verve Therapeutics position peaked at $314K in Q4 2021.
  • 92 funds tracked by Wall St. Rank held Verve Therapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.